Mumbai: Sun Pharma has announced the appointment of Richard Ascroft as the new North America (NAM) Chief Executive Officer (CEO).
In a statement shared via LinkedIn, the company said, “We are happy to announce Richard Ascroft has joined Sun Pharma as the new North America (NAM) Chief Executive Officer (CEO). An accomplished leader with an extensive background driving strategic growth through innovation, Richard brings more than three decades of experience to the helm of the U.S. and Canadian businesses.”
Ascroft expressed enthusiasm about his new role, stating, “I am honored to lead such a dynamic team committed to advancing Sun’s portfolio of generic, innovative and OTC medicines. The North America region is poised to bring new treatments to the market and drive significant growth for business. I look forward to building on our strong foundation, supporting patients throughout their journey and delivering the highest quality generic and innovative medicines to the people we serve.”
Prior to joining Sun, Ascroft held leadership roles at Takeda for over nine years, most recently serving as Senior Vice President, Head of US Plasma-Derived Therapies BU. He previously spent more than 22 years at Eli Lilly and Company.
Meanwhile, as previously reported by Medical Dialogues, Sun Pharma also named Kirti Ganorkar as the company’s next Managing Director, effective September 1, 2025, succeeding the company’s current Managing Director, Dilip Shanghvi. In the new role, Ganorkar will take over the responsibility for the company’s entire business and functions reporting to him.
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.
